白三烯抗体拮抗剂对支气管哮喘及合并过敏性鼻炎的临床治疗

目的观察白三烯抗体拮抗剂对支气管哮喘合并过敏性鼻炎的临床治疗效果。方法 120例支气管哮喘及合并过敏性鼻炎患者随机分为对照组和治疗组,各60例。对照组只用氯雷他定治疗,治疗组在氯雷他定治疗基础上加白三烯抗体拮抗剂孟鲁司特纳联合治疗,疗程6周,对比两组的治疗效果及不良反应发生情况。结果治疗组患者总有效率为88.33%高于对照组的68.33%,差异具有统计学意义(P<0.05);两组患者不良反应发生率比较差异无统计学意义(P>0.05)。结论白三烯抗体拮抗剂对支气管哮喘及合并过敏性鼻炎的临床治疗效果显著,值得在临床治疗中广泛应用。

孟鲁司特钠治疗小儿咳嗽变异性哮喘的临床观察

目的:观察孟鲁司特钠在治疗小儿咳嗽变异性哮喘中的临床疗效。方法:将97例咳嗽变异性哮喘患儿随机分为观察组51例和对照组46例。对照组予辅舒酮(丙酸氟替卡松气雾剂)早晚各一次,观察组予孟鲁司特钠每日睡前口服一次。结果:两组在达到临床症状缓解和消失所需时间及随访半年的复发率比较,均无显著差异(P>0.05)。结论:孟鲁司特钠治疗小儿咳嗽变异性哮喘疗效与激素相当,依从性好,益于推广。

布地奈德联合孟鲁司特治疗支气管哮喘的疗效观察

目的评价布地奈德联鲁司特治疗支气管哮喘的疗效;方法选择80例支气管哮喘患者随机分为对照组(40例)、治疗组(40例),对照组采用常规治疗,治疗组在对照组的基础上采用雾化吸入布地奈德联合口服孟鲁司特的方法治疗,1个疗程结束后评定疗效。结果治疗组总有效率达92.5%,对照组总有效率65%,治疗组在疗效上明显高于对照组,比较差异有显著性统计学意义(P<0.01);治疗期间两组均未出现明显不良反应。结论在常规治疗的基础上采用雾化吸入布地奈德联合口服孟鲁司特治疗支气管哮喘的方法疗效佳,而且也安全,在临床上值得推广。

辅舒酮气雾剂联合孟鲁司特治疗支气管哮喘的疗效研究

目的探讨辅舒酮气雾剂联合孟鲁司特治疗支气管哮喘的临床疗效;方法选择60例支气管哮喘患者随机分为两组,对照组和治疗组各30例,对照组予吸氧、抗炎、扩张支气管、全身糖皮质激素等常规基础治疗,治疗组在对照组的基础上吸入辅舒酮气雾剂联合口服孟鲁司特咀嚼片治疗,14天为一个疗程,一个疗程后比较两组患者的临床疗效、肺功能变化。结果治疗组临床总有效率为90%,高于对照组总有效率66.7%,两组疗效经Ridit分析,治疗组明显优于对照组(U=2.2733,p<0.05),治疗期间两组均未出现明显不良反应。结论在常规治疗的基础上吸入辅舒酮气雾剂联合孟鲁司特治疗支气管哮喘方法疗效佳,值得在临床上广泛推广。

Plasma Levels of Leukotriene B4 and Prostaglandin E2 Correlation with Endoscopic Changes after NSAID Gastropathies Pantoprazole Treatment in Patients with Cardiovascular Pathology

The article describes the pantoprazole healing effect on the gastroduodenal mucosa in patients with NSAID gastropathy. Two groups of patients were compared, depending on the treatment they have got group, which was taking 75 mg of enteric aspirin per day and the group, where pantoprazole has been added to aspirin in the usual dose. Mucosa assessment was studied using fibrogastroduodenoscopy and Lanza score. Also, the relationship between aggression factors that cause NSAID gastropathy and mucosal protection agents has been studied. It was proved that the pantoprazole influence reduces the ulcerative-erosive lesions amount. Stomach erosive lesions percentage decreased from 58.18% to 42.42%, stomach ulcers from 14.55% to 6.06%, duodenum erosive lesions decreased from 34.55% to 24.24%, duodenum ulcers deceased from 9.09% to 3.03%. A positive correlation between LTB4 and Lanza scale was checked after pantoprazole treatment, indicating an impact on the LTB4 reduction in ulcers healing in patients with NSAID gastropathy.